Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119696) titled 'Safety and Efficacy Analysis of TACE Combined with HAIC Versus TACE Alone in the Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter, Retrospective, Cohort Study' on March 2.
Study Type: Observational study
Study Design:
Sequential
Primary Sponsor: West China Hospital, Sichuan University
Condition:
Unresectable hepatocellular carcinoma (HCC)
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-03-02
Target Sample Size: The observation group of inoperable liver cancer:1200;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.h...